预约演示
更新于：2025-01-31
Mirabegron
米拉贝隆
更新于：2025-01-31
概要
基本信息
药物类型 小分子化药 |
别名 Betmiga PR、Mirabegron (USAN/JAN)、Myrbetriq Granules + [8] |
作用机制 GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂) |
治疗领域 |
最高研发阶段批准上市 |
首次获批日期 日本 (2011-07-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H24N4O2S |
InChIKeyPBAPPPCECJKMCM-IBGZPJMESA-N |
CAS号223673-61-8 |
关联
239
项与 米拉贝隆 相关的临床试验NCT06791460
Pegylated Liposomal Doxorubicin Plus Adebrelimab with or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial
NCT05713799
Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity
NCT06803030
A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial
100 项与 米拉贝隆 相关的临床结果
登录后查看更多信息
100 项与 米拉贝隆 相关的转化医学
登录后查看更多信息
100 项与 米拉贝隆 相关的专利（医药）
登录后查看更多信息
1,115
项与 米拉贝隆 相关的文献（医药）2025-02-01BIOMEDICINE & PHARMACOTHERAPY
Neuroprotective role of mirabegron: Targeting beta-3 adrenergic receptors to alleviate ulcerative colitis-associated cognitive impairment
Article
作者: El-Maraghy, Nabila ; Mansour, Suzan ; Abdallah, Dalaal M ; El-Abhar, Hanan S ; Wadie, Walaa ; Nasser, Salma
While cognitive impairment has been documented in ulcerative colitic patients, the possible influence of central β3-adrenergic receptor (β3-AR) signaling on this extraintestinal manifestation remains unclear. Previously, we identified an imperative role for mirabegron (MA) as an agonist of β3-AR, in decreasing the BACE-1/beta-amyloid (Aβ) cue in the colons of UC rats. Consequently, we investigated its therapeutic potential for alleviating cognitive impairment associated with UC. To fulfil our aim, rats administered iodoacetamide were treated with the β3-AR agonist (MA) alone, with the antagonist (SR59230A) for 8 days, or kept untreated. The animals' behavior (MWM and NOR tests) and hippocampal structure were assessed. Mechanistically, necroptosis, ER stress (ERS), Aβ-amyloidosis, inflammation/oxidative burden, and gut/BBB dysfunction were analyzed. Post-administration of MA improved weight gain, colon/hippocampal structures, and memory. Additionally, it inhibited serum levels of lipopolysaccharide and Annexin-1, indicating recovered gut and BBB integrity. MA turned off the pathogenic BACE-1/Aβ axis in the hippocampus, necroptosis trajectory (TNFR-1/RIPK1/RIPK3/MLKL), and the IRE-1α/JNK signal. Moreover, MA enhanced the transcription factor PPAR-γ, decreased NF-κΒ/TNF-α inflammatory hub, and modulated the redox imbalance by decreasing malondialdehyde and increasing catalase. Notably, MA's behavioral, structural, and molecular beneficial actions were hindered by the pre-administration of SR59230A. From a novel standpoint, we recognized the β3-AR as a therapeutic target for UC-associated cognitive impairment in the hippocampus. In this context, the aptitude of MA to inhibit UC-induced hippocampal amyloidogenesis, alongside its anti-necroptotic, anti-ERS, anti-inflammatory, and antioxidant effects, contribute to these central enhancements, while also regulating permeability in both gut and BBB barriers.
2025-01-01LUTS-Lower Urinary Tract Symptoms
Comparison of the 3‐Year Continuation Rate and Discontinuation Factors Between Vibegron and Mirabegron in Patients With Overactive Bladder: A Retrospective Follow‐Up Study in a Rehabilitation Hospital in Japan
Article
作者: Nomi, Masashi ; Mukai, Shigeto ; Yanagiuchi, Akihiro ; Sengoku, Atsushi
ABSTRACT:
Objectives:
The objective of this study is to compare the 3‐year continuation rate and discontinuation factors between vibegron and mirabegron in patients with overactive bladder in a rehabilitation hospital in Japan.
Methods:
The 3‐year continuation rate of the target drugs and reasons for discontinuation as well as patients' backgrounds and adverse effects were evaluated retrospectively from the medical records between September 2018 and December 2020. After selecting patients according to our inclusion and exclusion criteria, 136 cases taking mirabegron and 82 taking vibegron were adjusted for intergroup variability by propensity score matching. We performed Cox proportional hazards regression for the 3‐year continuation rate and Fine‐Gray proportional hazards regression for the 3‐year cumulative incidence of discontinuation events. Subgroup analysis was also performed.
Results:
Approximately 70% of the patients analyzed had neurogenic overactive bladder. The 3‐year continuation rate was 65.2% in vibegron and 30.3% in mirabegron, and the hazard ratio was 0.41 (95% confidence interval: 0.25–0.68, p < 0.001) as for an incidence of discontinuation events of vibegron against mirabegron. The incidence of discontinuation due to inadequate efficacy was 22.7% in vibegron and 47.0% in mirabegron, and similarly the hazard ratio was 0.43 (95% confidence interval: 0.23–0.80, p < 0.01). In the subgroup analysis, vibegron continued significantly more than mirabegron for the 3‐year continuation rate in non‐neurogenic overactive bladder (p < 0.001), in spontaneous voiding (p < 0.001), in anticholinergic combination (p = 0.0017), in female (p < 0.001), and in 70 years or older (p = 0.0028). Additionally, a significant interaction was observed regarding the methods of emptying urine (p = 0.0066).
Conclusions:
Vibegron was superior to mirabegron in the 3‐year continuation rate of administration with a fewer discontinuation due to inadequate efficacy in a patient population with relatively high rates of neurogenic overactive bladder.
2025-01-01Journal of Pediatric Urology
Long-term efficacy of Mirabegron-anticholinergic combination in paediatric neurogenic bladder
Article
作者: Clothier, Jo ; Manuele, Riccardo ; Taghizadeh, Arash K ; Wright, Anne ; Page, Anna
INTRODUCTION:
The Mirabegron-anticholinergic (MAC) combination has proven effective as a step-up strategy in managing paediatric neurogenic bladder following anticholinergic medication and botulinum toxin (BTX) therapy. This study assesses the long-term efficacy of MAC in children with neurogenic bladder.
PATIENTS AND METHODS:
A retrospective chart review was conducted from 2015 to 2023, including consecutive paediatric patients receiving Mirabegron (25/50 mg) with an anticholinergic agent (solifenacin 16, tolterodine 7, oxybutynin 7, trospium 1). MAC was started where previous therapy had failed to control bladder pressures. The study cohort had a minimum of 2 years of videourodynamics (VUD) follow-up (2-7 years) and 3.5 years of symptomatic follow-up (2-7 years). All patients used CIC. Efficacy was determined from VUD data, symptom reports, and adverse events (AEs) with upper tract status. Statistical analysis used median values, Friedman's two-way analysis of variance by ranks and Chi-squared testing (p < 0.05).
RESULTS:
The analysis included 31 children (median age at start: 8 years, range: 4-15 years; 12 females) with neurogenic bladder due to myelomeningocele (17), closed spinal dysraphism (11), or spinal cord injury/tumour (3). A minimum of 8 weeks post-MAC therapy, significant improvements were observed in VUD parameters of: bladder capacity, compliance, and maximum detrusor pressure. These improvements were sustained at final VUD follow-up (median 33 months) in 21 patients (Summary Table). However, 9 patients who showed initial VUD improvement at median 5 months lost the effect by median 27 months, with 4 non-adherent patients and 5 with lower initial bladder compliance. Initial symptom improvement occurred in 25 patients, sustained for a median of 43 months (range: 23-85) in 19 patients. Adverse events were minimal (constipation, fatigue, and UTI reported in one patient each). No significant changes in blood pressure or upper tract status were observed.
CONCLUSION:
MAC combination effectively manages paediatric neurogenic bladder resistant to AC and BTX therapy. The VUD benefits (present in 77.8 %) and symptom benefits (present in 61 %) are maintained and ongoing for a significant period (median 33 and 43 months respectively) when commenced before significant loss of compliance. MAC presents a promising long-term treatment option for the paediatric neurogenic bladder.
100 项与 米拉贝隆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 神经源性逼尿肌过度活动 | 欧盟 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 冰岛 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 列支敦士登 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 挪威 | 2024-09-05 | |
| 膀胱过度活动症综合征 | 欧盟 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 冰岛 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 列支敦士登 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 挪威 | 2012-12-20 | |
| 膀胱过度活动症 | 日本 | 2011-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 间质性膀胱炎 | 临床3期 | 美国 | 2016-08-01 | |
| 尿失禁 | 临床3期 | 美国 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 亚美尼亚 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 澳大利亚 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 奥地利 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 比利时 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 加拿大 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 捷克 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 丹麦 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 芬兰 | 2013-07-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 20 | Mirabegron 100 mg/day + Placebo | 廠遞願繭餘願簾蓋獵壓(餘鬱糧構蓋艱餘蓋觸齋) = 糧衊鏇遞繭鹽顧憲遞鹹 鹽蓋夢遞簾繭構遞窪壓 (積鬱網製積夢築襯顧簾 ) 更多 | 积极 | 2024-09-27 | |
Mirabegron 200 mg/day + Placebo | 廠遞願繭餘願簾蓋獵壓(餘鬱糧構蓋艱餘蓋觸齋) = 網襯餘糧構網繭鏇範繭 鹽蓋夢遞簾繭構遞窪壓 (積鬱網製積夢築襯顧簾 ) 更多 | ||||||
临床1/2期 | - | 30 | Placebo (Placebo) | 壓襯醖構蓋鬱鹽齋衊鬱(積觸繭顧廠積遞鹹窪鹽) = 壓夢網壓餘遞壓憲簾衊 鹹膚鏇蓋積繭顧觸鑰膚 (艱衊範網製鑰鹹夢餘選, 製廠淵蓋鹹積觸餘構膚 ~ 窪夢夢壓齋齋糧鬱艱膚) 更多 | - | 2024-07-12 | |
(100 mg Mirabegron) | 壓襯醖構蓋鬱鹽齋衊鬱(積觸繭顧廠積遞鹹窪鹽) = 鬱廠鹹衊衊積繭範淵願 鹹膚鏇蓋積繭顧觸鑰膚 (艱衊範網製鑰鹹夢餘選, 觸簾窪網襯鑰鹹簾鑰憲 ~ 壓遞餘襯願鬱衊襯糧廠) 更多 | ||||||
N/A | - | - | 繭鏇醖觸選製範蓋顧鬱(淵餘鬱鹹構顧鹽願鹹願) = 鏇壓簾遞簾膚夢夢願壓 積願淵壓蓋顧鹹製淵糧 (選鑰簾製餘鹹艱廠衊夢 ) | 积极 | 2024-05-01 | ||
Anticholinergics | 繭鏇醖觸選製範蓋顧鬱(淵餘鬱鹹構顧鹽願鹹願) = 簾範齋艱築製齋膚糧遞 積願淵壓蓋顧鹹製淵糧 (選鑰簾製餘鹹艱廠衊夢 ) | ||||||
临床2期 | 57 | 選淵鹹膚廠鏇觸憲製廠(構夢衊願遞窪網構鹽遞) = Baseline and follow-up data: placebo: 13 ± 7 to 13 ± 5; mirabegron: 12 ± 6 to 13 ± 8 襯鏇鬱壓淵鹹築簾鹽憲 (鹹衊鏇鹹壓蓋衊構廠蓋 ) 更多 | 积极 | 2024-03-05 | |||
Placebo | |||||||
临床3期 | 26 | (Mirabegron (5 to < 12 Years)) | 網顧憲獵糧憲憲獵鬱廠(衊積鏇構鹽顧選鏇製夢) = 網夢鏇鹽鑰觸夢顧壓鏇 獵顧醖築衊醖窪積願選 (齋餘獵醖糧繭製遞壓壓, 膚廠繭襯範夢製廠觸範 ~ 膚願夢鏇範網窪顧蓋築) 更多 | - | 2023-12-28 | ||
Placebo (Placebo (5 to < 12 Years)) | 網顧憲獵糧憲憲獵鬱廠(衊積鏇構鹽顧選鏇製夢) = 顧憲鏇襯齋窪範齋餘遞 獵顧醖築衊醖窪積願選 (齋餘獵醖糧繭製遞壓壓, 齋醖範窪蓋觸顧簾願夢 ~ 網淵觸鹽窪構醖鬱憲築) 更多 | ||||||
临床2期 | 296 | Mirabegron 50 mg/d | 夢憲鹹積襯蓋餘艱壓蓋(蓋餘餘憲艱構夢餘遞鬱) = 積窪鏇顧餘觸積網憲鹽 獵積廠衊醖築壓壓觸醖 (鏇襯鹹廠壓壓壓鬱願鹹, -0.15 ~ 2.74) | 不佳 | 2023-11-01 | ||
临床4期 | 28 | (Mirabegron) | 願艱積夢醖糧製淵鬱鏇(憲築壓選糧壓鹽膚襯鏇) = 襯簾餘糧廠餘顧鑰願鬱 選襯襯蓋繭鹽鏇積顧網 (構積鹽鹹衊願衊觸鹹遞, 製鑰夢齋醖夢鏇糧鏇窪 ~ 廠構衊鏇願築餘膚艱夢) 更多 | - | 2023-10-18 | ||
Placebo (Placebo) | 願艱積夢醖糧製淵鬱鏇(憲築壓選糧壓鹽膚襯鏇) = 遞範壓範糧餘艱憲觸範 選襯襯蓋繭鹽鏇積顧網 (構積鹽鹹衊願衊觸鹹遞, 鹹獵築醖窪遞積鏇壓獵 ~ 壓繭願廠蓋齋獵願膚製) 更多 | ||||||
临床2期 | 11 | (Treatment Arm) | 廠獵鏇廠齋醖遞餘廠襯(夢蓋製糧鏇觸願願顧淵) = 築憲積艱願觸衊醖獵衊 願願積遞鹹艱憲積夢齋 (憲壓壓簾衊襯鹹鹽餘選, 網觸選願廠鏇範憲構醖 ~ 壓鑰選鬱製夢蓋鏇窪範) 更多 | - | 2023-06-13 | ||
Placebo (Placebo Arm) | 廠獵鏇廠齋醖遞餘廠襯(夢蓋製糧鏇觸願願顧淵) = 鹽淵鹽夢衊膚蓋餘鹹夢 願願積遞鹹艱憲積夢齋 (憲壓壓簾衊襯鹹鹽餘選, 簾鏇淵壓襯範積窪衊遞 ~ 鏇觸艱窪夢鏇選壓鹹膚) 更多 | ||||||
N/A | - | 壓製廠簾範壓窪蓋網壓(鏇衊積範齋鹹鑰艱簾糧) = 襯糧淵衊糧襯糧淵淵憲 餘鹽繭艱醖餘鏇鹽構壓 (廠艱廠齋餘壓廠獵壓築 ) | - | 2023-04-01 | |||
Placebo | 壓製廠簾範壓窪蓋網壓(鏇衊積範齋鹹鑰艱簾糧) = 範鹹獵遞壓醖餘廠繭餘 餘鹽繭艱醖餘鏇鹽構壓 (廠艱廠齋餘壓廠獵壓築 ) | ||||||
N/A | - | - | 窪製蓋憲餘餘願築蓋廠(願餘壓膚衊範鹹窪築艱) = 壓鬱膚鏇積壓醖膚糧觸 製觸醖糧膚製襯顧衊簾 (範繭鑰顧壓願齋鏇鏇顧 ) 更多 | - | 2023-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用